Drug Database
FL

Fluosol-DA (Fluosol)

✓ Approved

Mitsubishi Tanabe Pharma Corporation · Small Molecule · Small Molecule

What is Fluosol-DA?

Fluosol-DA is a small molecule developed by Mitsubishi Tanabe Pharma Corporation. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesFluosol
CompanyMitsubishi Tanabe Pharma Corporation
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Mitsubishi Tanabe Pharma Corporation

Therapeutic Indications

Fluosol-DA is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersAnaemia✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasm malignant✓ Approved

Related Research Articles

PubMedBritish journal of haematology2026-07-25

Comparison of outcomes after DA-EPOCH-R or GMALL high-intensity therapy for front-line treatment of Burkitt lymphoma: A retrospective cohort.

Schulz Eduard E, Posch Florian F, Friedrich Kristina K, Neumeister Peter P et al.

In this retrospective cohort of adult Burkitt lymphoma, DA-EPOCH-R showed no signal of inferior survival or relapse risk compared with GMALL-based high-intensity therapy. Outcomes were driven mainly by established prognostic factors, particularly age, advanced stage and Burkitt lymphoma International Prognostic Index.

PMID 42500826
Read full article →
PubMedBehavioural brain research2026-07-25

Multiple Stimulations of Chemoluminescent-Expressing Mesenchymal-Derived Dopaminergic Transplants Safely Reinforce Limb-Use Control Restoration During Swimming in a Unilateral Parkinson's Disease Model.

Cammarano Tommie L TL, Galik Stefani M SM, Anderson Kevin A KA, Bloesch Emily E et al.

In Parkinson's disease (PD), dopaminergic (DA) neurons deteriorate within the substantia nigra pars compacta (SNc), causing movement difficulties. This deterioration can be modeled in rats given large, unilateral DA-depleting lesions of the nigrostriatal pathway using the neurotoxin 6-hydroxydopamine. The behavioral benefits promoted by classic L-DOPA pharmacotherapy typically do not include skilled limb use restoration. Among deteriorative diseases, the single neurotransmitter loss in PD allows for a more discrete or focused replacement goal. Stem cell therapy (SCT) would be more likely to help restore skilled limb use if it integrates successfully into the host. We surmise that more stable or persistent PD SCT will require active guidance or context signaling while connecting within a hospitable host environment to integrate successfully and ensure behavior-responsive host control. To explore this, we examined the supportive effects of swimming exercise alone or exercise with transplantation of modified LMO3-containing mesenchymal stem cell (MSC)-derived dopaminergic transplants, and, in both cases with or without varying degrees of swim-correlated direct chemogenic activated optogenetic stimulation of the transplanted cells. We were interested in whether increasing selective and behavior-correlated transplant stimulation more than once during early integration might guide reconstructive events and enhance behavioral improvement following DA loss without producing undesirable repercussions. Our study evaluated forelimb cooperative control in rats using a recorded swimming task to assess exercise/transplant/stimulation-related improvements. Combined transplant stimulation and swimming facilitated transplant-derived forelimb cooperation during swimming after a single exposure. Two distinct stimulations supported this recovery both safely, and more effectively, than just one.

PMID 42497964
Read full article →
PubMedFrontiers in oncology2026-07-25

Reconfiguring robotic surgery in head and neck practice: transition from multi-port to single-port with early clinical outcomes.

Chen Shih-Wei SW, Hsiao Ying-Lyung YL, Pan Chang-Yo CY, Lin Chuck C et al.

The integration of the da Vinci single-port (SP) platform into head and neck practice represents a major transition from conventional multi-port robotic systems, yet real-world data on early institutional adoption remain limited. This study evaluated the clinical integration of the SP platform during an early implementation period, with particular focus on case accrual, diversification of surgical access routes, surgeon-specific adoption patterns, and temporal evolution of case selection. This retrospective observational study included consecutive robotic head and neck procedures performed with the da Vinci SP system at a single institution during a 9-month transition period prior to the installation of a second SP system. Clinical, operative, and perioperative variables were extracted from an amended institutional dataset and operative records. Cases were analyzed overall, compared between the 2 primary surgeons, and chronologically stratified into Early and Later phases. A total of 64 cases were performed, including 34 malignant (53.1%) and 30 benign (46.9%) lesions. Case accrual increased steadily throughout the study period. Transoral surgery was the most common access route (42/64, 65.6%), followed by transoral plus transcervical (12/64, 18.8%), transcervical alone (5/64, 7.8%), and retroauricular access (5/64, 7.8%). Surgeon 1 performed 51 cases and treated an older population with significantly higher rates of tobacco, alcohol, and betel quid exposure, more malignant disease, and broader anatomic distribution. Surgeon 2 performed 13 cases, all through a transoral approach, predominantly for benign lesions. A chronological comparison between the Early and Later phases showed stable surgeon distribution, pathology patterns, and approach patterns, but oral cavity cases and reconstructive procedures became more prominent in the Later phase. Cumulative accrual curves for benign and malignant disease progressed in parallel, suggesting that SP adoption expanded across both oncologic and benign indications rather than being confined to a single clinical niche. Early institutional integration of the da Vinci SP platform was associated with steady case accrual, expansion of operative access pathways, and broad adoption across malignant and benign head and neck indications. These findings provide real-world evidence that transition from multi-port to single-port robotic surgery can be achieved successfully within a high-volume head and neck program.

PMID 42500283
Read full article →
PubMedJournal of ethnopharmacology2026-07-25

Da-Jian-Zhong decoction restores the gut-brain balance in diarrhea-predominant irritable bowel syndrome rats via gut microbiota-bile acid axis.

Gao Huan-Qing HQ, Zhang Ning N, Li Ge-Ning GN, Wen Li L et al.

Da-Jian-Zhong decoction (DJZD), a Chinese medicinal formula, exhibits therapeutic effects in the clinical management of diarrhea-predominant irritable bowel syndrome (IBS-D). Accumulating studies have demonstrated that DJZD can regulate the gut-brain balance in IBS-D model rats; however, its underlying molecular mechanism remains unclear. To explore the potential mechanism by which DJZD restores the gut-brain axis in IBS-D model rats. Firstly, the therapeutic effects of DJZD in IBS-D model rats were evaluated based on the Bristol stool scale, abdominal withdrawal reflex (AWR) score, open field test (OFT) behavior, intestinal barrier function, and brain-gut peptide levels. Moreover, alterations in gut microbiota was detected using sequencing of the whole microbial genome. Subsequently, fecal microbiota transplantation (FMT) was performed to explore whether the regulatory effect of DJZD on the gut-brain axis against IBS-D was dependent on gut microbiota. The UHPLC-QTRAP-MS/MS was utilized to analyze bile acids (BAs) profiles and identify gut microbiota-derived BAs metabolites responsible for the beneficial effects of DJZD. Finally, the role of BAs metabolites in restoring the gut-brain axis was further verified using the IBS-D model rats. Treatment with DJZD not only decreased AWR scores, improved stool score and intestinal barrier function, but also enhanced sucrose preference and changed OFT performance of IBS-D rats. Meanwhile, DJZD normalized the levels of 5-hydroxytryptamine (5-HT) and substance P (SP) in both the colon and hippocampus. Fecal microbiota harvested from DJZD-treated rats also reversed these IBS-D-associated pathological manifestations. Moreover, DJZD notably elevated the contents of secondary BAs (SBAs) in IBS-D rats, particularly norchenodeoxycholic acid (NorDCA), lithocholic acid (LCA), deoxycholic acid (DCA), and 3β-ursodeoxycholic acid (3β-UDCA). The elevated SBAs were positively correlated with the relative abundances of Akkermansia sp., Ruminococcus sp., and Clostridium sp. This could be attributed to the ability of these bacteria to produce bile salt hydrolases (BSH) and 7α-hydroxysteroid dehydrogenases (7α-HSDH). Additionally, administration with an LCA and DCA mixture was found to improve intestinal and brain dysfunction and restored abnormal 5-HT and SP levels. DJZD restores gut-brain balance in IBS-D rats by regulating gut microbiota-bile acid axis, which provides a promising therapeutic strategy for IBS-D via targeting bile acid metabolites and intestinal bacteria.

PMID 42498089
Read full article →
PubMedJournal of breath research2026-07-25

A novel approach to non-invasive lung cancer screening via exhaled breath analysis using proton transfer reaction time-of-flight mass spectrometry.

Hernández Camarillo Maribel M, Campos-González Joshua J, Vera-Nuñez Fernando F, Hernández-López Enrique E et al.

Lung cancer (LC) remains a global public health problem. To minimize late diagnosis, new detection techniques are needed. The analysis of volatile organic compounds (VOCs) in human breath (the volatilome) represents a non-invasive alternative to current methods for the early detection of LC. In this study, VOCs were determined in the breath of individuals with LC (N=22) and without LC (non-LC, N=21) using proton transfer reaction time-of-flight mass spectrometry (PTR-ToF-MS). Orthogonal partial least squares discriminant analysis (oPLS-DA) and hierarchical cluster analysis (HCA) were conducted on a subset of 54 VOC ions (out of 180). Twenty-one of the 54 VOC ions were detected in exhaled breath. CH₄O₃H⁺ and C₈H₇NH⁺ were found only in participants without cancer. Among the 19 common ions present in both cohorts, the intensities of 8 ions were statistically different. The LC/non-LC ratios were observed for C₄H₈O₂H⁺, followed by C₃H₄OH⁺, C₂H₂OH⁺, C₂H₃ONH⁺, C₃H₄H⁺, C₃H₂H⁺, C₄H₈H⁺, and C₆H₈H⁺. Spearman correlation analysis could be used to differentiate metabolic processes or pathways between cohorts. Diagnostic ratio is a potential tool to classify individuals with or without lung cancer. This study provides exploratory evidence for exhaled VOCs as potential LC biomarkers and positions them as a complement to current diagnostic pathways, with a potential role in supporting early triage and clinical decision-making.

PMID 42497886
Read full article →
PubMedDose-response : a publication of International Hormesis Society2026-07-25

Integrating Network Pharmacology and Experimental Validation Reveals EGFR/PI3K/Akt Axis Mediates Ibrutinib-Induced Cardiotoxicity.

Guan Yingxia Y, Mei Jiaqi J, He Yuanqiao Y, Lu Mei M et al.

This study aims to systematically explore the molecular mechanism underlying ibrutinib-induced cardiotoxicity. Network toxicology was applied using DrugBank, PharmMapper, GeneCards, OMIM, and TTD databases to identify overlapping targets between ibrutinib and myocardial injury, followed by PPI network construction (STRING; confidence ≥0.7) and GO/KEGG enrichment analyses (Metascape). Molecular docking (AutoDock Vina) verified ibrutinib's binding affinity to core targets. In vitro, H9C2 cardiomyocytes were exposed to ibrutinib (0, 10, 20, 40, and 80 μM) for 24 h; CCK-8, DCFH-DA, EdU, and Calcein-AM/PI assays were performed to assess cell viability, ROS levels, proliferation, and cell death, respectively. Western blot analyzed phosphorylation of EGFR/PI3K/Akt/mTOR pathway proteins. A total of 42 overlapping targets were screened from 337 ibrutinib-related targets and 471 myocardial injury-related genes. PPI network analysis identified EGFR, AKT1, SRC, ESR1, and CASP3 as hub genes, and KEGG enrichment analysis identified the PI3K-Akt pathway as the most significantly enriched cascade. Molecular docking confirmed that ibrutinib stably bound BTK and EGFR with a binding energy of -30.2 kcal/mol and formed multiple hydrogen bonds and salt bridges (2.2-3.2 Å). In H9C2 cells, ibrutinib dose-dependently reduced viability (IC50 = 119.49 μM), increased ROS production (40 and 80 μM), inhibited proliferation (10 and 20 μM), and promoted cell death (5 and 10 μM). Western blot confirmed that ibrutinib significantly downregulated phosphorylation of PI3K p85, Akt (Ser473), mTOR (Ser2448), and p70S6K (Thr389) without altering total protein expression. Ibrutinib induces cardiotoxicity by targeting BTK/EGFR and inhibiting the downstream EGFR/PI3K/Akt/mTOR pathway, providing a mechanistic framework for clinical safety management of BTK inhibitors.

PMID 42500305
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Fluosol-DA